About the Program
Program Overview
While an increasing number of options are available or in development for effectively treating patients with HCV infection, many clinicians find it challenging to keep abreast of important developments in HCV therapeutics. To address this problem, this CME dinner program series will use case studies to highlight and discuss the relative merits and clinical significance of new findings in HCV medicine presented at the 49th Annual Meeting of the European Association for the Study of the Liver (49th EASL).
Because the focus of the dinner programs will be on case studies, participants will need to be familiar with data from the 49th EASL that may be applied and discussed. Therefore, prior to attending a dinner program, participants will view an Internet presentation that summarizes and discusses the key data presented at the 49th EASL. As a result of this blended learning approach, participants will not only gain an increased understanding of key data presented at the 49th EASL, they will also be better prepared to address their HCV patients' health needs and provide optimal care, which should improve adherence, increase individualized care, reduce adverse effects and drug-drug interactions, and improve quality of life.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc.. It is not a session created by or presented at the 49th EASL and it is not sanctioned by the 49th EASL.
Target Audience
This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the treatment and management of patients with HCV infection.
Learning Objectives
After completing this activity, the participant should be better able to:
Program Dates and Locations
Tuesday, April 22, 2014
Los Angeles, CA |
Thursday, May 1, 2014
Miami, FL
|
Tuesday, April 29, 2014
Chicago, IL |
Tuesday, May 6, 2014
Boston, MA |
Tuesday, April 29, 2014
San Francisco, CA |
Tuesday, May 6, 2014
New York, NY
|
Thursday, May 1, 2014
Baltimore, MD |
Tuesday, May 13, 2014
Houston, TX |
Course Director
Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Faculty
Nezam H. Afdhal, MD
Professor of Medicine
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center,
Beth Israel Deaconess Medical Center
Boston, Massachusetts
|
Fred Poordad, MD
VP, Academic and Clinical Affairs
The Texas Liver Institute
Clinical Professor of Medicine
University of Texas Health Science Center
San Antonio, Texas
|
Maurizio Bonacini, MD
Director, HIV-Liver Clinic
Department of Transplantation
California Pacific Medical Center
San Francisco, California |
Sammy Saab, MD
Professor of Medicine and Surgery
The Pfleger Liver Institute
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California
|
Lennox Jeffers, MD
Chief of Hepatology
Miami VA Medical Center
Associate Chief
Center for Liver Disease
Professor of Medicine
University of Miami's School of Medicine
Miami, Florida
|
|
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Disclaimer
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Sunshine Act
As of August 1, 2013, pharmaceutical companies are required by the open payments act (AKA Sunshine Act) to account for certain transfers of value provided to physicians. The federal guidance for the Sunshine Act provides exceptions for CME expenses that meet certain criteria. We believe the program to which you are invited meets these exceptions, and therefore we will not be collecting, nor reporting, any information gathered from this program. If federal guidance is further clarified in the future, we will then provide that information to the supporting pharmaceutical companies to the best of our ability.
Supported by an unrestricted educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
|